PHATHOM PHARMACEUTICALS INC's ticker is PHAT and the CUSIP is 71722W107. A total of 59 filers reported holding PHATHOM PHARMACEUTICALS INC in Q3 2020. The put-call ratio across all filers is - and the average weighting 1.5%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $646,861 | -3.0% | 62,802 | 0.0% | 1.38% | -3.4% |
Q1 2024 | $666,957 | +16.3% | 62,802 | 0.0% | 1.42% | +222.2% |
Q4 2023 | $573,382 | -12.0% | 62,802 | 0.0% | 0.44% | -27.7% |
Q3 2023 | $651,257 | -27.6% | 62,802 | 0.0% | 0.61% | -24.7% |
Q2 2023 | $899,325 | +100.6% | 62,802 | 0.0% | 0.81% | +90.8% |
Q1 2023 | $448,406 | -36.4% | 62,802 | 0.0% | 0.42% | -46.0% |
Q4 2022 | $704,638 | -26.8% | 62,802 | -27.8% | 0.79% | -37.5% |
Q3 2022 | $963,000 | +31.2% | 86,940 | 0.0% | 1.26% | +27.4% |
Q2 2022 | $734,000 | -38.0% | 86,940 | 0.0% | 0.99% | -27.9% |
Q1 2022 | $1,183,000 | -57.6% | 86,940 | 0.0% | 1.37% | -68.9% |
Q3 2021 | $2,791,000 | -5.2% | 86,940 | 0.0% | 4.41% | +20.0% |
Q2 2021 | $2,943,000 | -9.9% | 86,940 | 0.0% | 3.68% | -0.3% |
Q1 2021 | $3,265,000 | +13.1% | 86,940 | 0.0% | 3.69% | +44.6% |
Q4 2020 | $2,888,000 | -9.4% | 86,940 | 0.0% | 2.55% | -43.3% |
Q3 2020 | $3,188,000 | +11.4% | 86,940 | 0.0% | 4.50% | +53.8% |
Q2 2020 | $2,861,000 | – | 86,940 | – | 2.92% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Medicxi Ventures Management (Jersey) Ltd | 7,464,572 | $76,885,092 | 22.93% |
Propel Bio Management, LLC | 869,927 | $8,960,248 | 5.81% |
Catalys Pacific, LLC | 721,962 | $7,436,208 | 5.61% |
Checkpoint Capital L.P. | 875,000 | $9,012,500 | 5.43% |
Frazier Life Sciences Management, L.P. | 10,109,279 | $104,125,574 | 4.87% |
Carlyle Group Inc. | 3,496,808 | $35,842,282 | 3.40% |
Decheng Capital LLC | 850,000 | $8,755,000 | 2.68% |
Saturn V Capital Management LP | 593,306 | $6,111,052 | 2.31% |
ORACLE INVESTMENT MANAGEMENT INC | 225,000 | $2,317,500 | 2.16% |
Ghost Tree Capital, LLC | 600,000 | $6,180,000 | 1.94% |